Femasys Announces Third Quarter Financial Results for 2025
Provided By GlobeNewswire
Last update: Nov 14, 2025
– FDA Approval to Advance Final FemBloc® Trial with Clear Pathway to Potentially Achieve U.S. FDA Approval –
– $12 Million Financing Strengthens Balance Sheet and Extends Cash Runway –
Read more at globenewswire.comNASDAQ:FEMY (12/3/2025, 11:15:23 AM)
0.8517
-0.04 (-4.3%)
Find more stocks in the Stock Screener
